Table 1.

Association of IL28B polymorphisms with HCV clearance in chronic hepatitis C

Response to treatment Genotype NR SVR Prop. SVRb Univariate models Multivariate modelsd 
     OR(95% CI) P OR (95% CI) P 
All viral genotypesa (n = 540)         
TT/-G TT/TT 37 152 0.80     
 TT/-G 131 161 0.55     
 -G/-G 35 24 0.41 0.38 (0.28–0.51) 2.51−10 0.27 (0.17–0.45) 2.70−7 
rs12979860 CC 43 146 0.77     
 CT 126 163 0.56     
 TT 34 28 0.45 0.46 (0.35–0.62) 1.52−7 0.37 (0.23–0.59) 2.47−5 
Viral genotype 1 and 4a (n= 288)         
TT/-G TT/TT 22 60 0.73     
 TT/-G 112 62 0.36     
 -G/-G 26 6 0.19 0.25 (0.16–0.40) 4.61−9 0.16 (0.08–0.33) 2.75−7 
rs12979860 CC 24 56 0.70     
 CT 109 64 0.37     
 TT 27 8 0.23 0.31 (0.20–0.49) 2.24−7 0.22 (0.11–0.41) 3.46−6 
Viral genotype 2 and 3c (n = 252)         
TT/-G TT/TT 15 92 0.86     
 TT/-G 19 99 0.84     
 -G/-G 9 18 0.67 0.36 (0.15–0.86) 2.13−2 1.33 (0.22–7.94) 7.57−1 
rs12979860 CC 19 90 0.83     
 CT 17 99 0.85     
 TT 7 20 0.74 0.54 (0.21–1.38) 2.01−1 1.48 (0.26–8.53) 6.59−1 
Spontaneous clearance (n = 633)a Genotype CRI SC  OR(95% CI) P OR (95% CI) P 
TT/-G TT/TT 189 63      
 TT/-G 292 29      
 -G/-G 59 1  0.28 (0.18–0.43) 8.68−9 0.30 (0.19–0.47) 1.54−7 
rs12979860 CC 189 62      
 CT 289 30      
 TT 62 1  0.29 (0.19–0.45) 1.66−8 0.31 (0.20–0.49) 3.64−7 
Response to treatment Genotype NR SVR Prop. SVRb Univariate models Multivariate modelsd 
     OR(95% CI) P OR (95% CI) P 
All viral genotypesa (n = 540)         
TT/-G TT/TT 37 152 0.80     
 TT/-G 131 161 0.55     
 -G/-G 35 24 0.41 0.38 (0.28–0.51) 2.51−10 0.27 (0.17–0.45) 2.70−7 
rs12979860 CC 43 146 0.77     
 CT 126 163 0.56     
 TT 34 28 0.45 0.46 (0.35–0.62) 1.52−7 0.37 (0.23–0.59) 2.47−5 
Viral genotype 1 and 4a (n= 288)         
TT/-G TT/TT 22 60 0.73     
 TT/-G 112 62 0.36     
 -G/-G 26 6 0.19 0.25 (0.16–0.40) 4.61−9 0.16 (0.08–0.33) 2.75−7 
rs12979860 CC 24 56 0.70     
 CT 109 64 0.37     
 TT 27 8 0.23 0.31 (0.20–0.49) 2.24−7 0.22 (0.11–0.41) 3.46−6 
Viral genotype 2 and 3c (n = 252)         
TT/-G TT/TT 15 92 0.86     
 TT/-G 19 99 0.84     
 -G/-G 9 18 0.67 0.36 (0.15–0.86) 2.13−2 1.33 (0.22–7.94) 7.57−1 
rs12979860 CC 19 90 0.83     
 CT 17 99 0.85     
 TT 7 20 0.74 0.54 (0.21–1.38) 2.01−1 1.48 (0.26–8.53) 6.59−1 
Spontaneous clearance (n = 633)a Genotype CRI SC  OR(95% CI) P OR (95% CI) P 
TT/-G TT/TT 189 63      
 TT/-G 292 29      
 -G/-G 59 1  0.28 (0.18–0.43) 8.68−9 0.30 (0.19–0.47) 1.54−7 
rs12979860 CC 189 62      
 CT 289 30      
 TT 62 1  0.29 (0.19–0.45) 1.66−8 0.31 (0.20–0.49) 3.64−7 

CRI, chronic infection; SC, spontaneous clearance; NR, nonresponse to treatment; OR, odds ratio; CI, confidence interval; Prop, proportion.

a

Odd ratios and p-values are for an additive model, accounting for increased effect of one or two copies of the mutant allele.

b

Data indicate the proportion of patients with SVR for indicated host and viral genotypes.

c

Odd ratios and p-values are for a recessive model, comparing the presence of two copies versus zero or one copies of the mutant allele.

d

Multivariate models are adjusted for age and sex (spontaneous clearance), as well as HCV RNA level, fibrosis stage, and, whenever appropriate, viral genotype (response to treatment). Multivariate models include a smaller number of patients, due to missing covariates in some patients (n = 360 for all genotypes, n = 195 for genotypes 1 and 4, and n = 165 for genotypes 2 and 3). However, the results of univariate analyses restricted to the subset of individuals with all covariates were concordant with those of the whole group.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal